ArticleScientific reports2025
Effects of Paeoniae Radix Rubra on lowering lipid via bioinformatics and gut microbiome.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Hyperlipidemia, a metabolic disorder characterized by abnormal lipid levels, is closely linked to an increased risk of cardiovascular disease. In this study, we investigated the hypolipidemic properties of Paeoniae Radix Rubra and its regulatory effects on gut microbiota composition in a high-fat diet model. Using UHPLC-QE-MS/MS, we identified its chemical constituents and applied bioinformatics, network pharmacology, and molecular docking to virtually screen for bioactive compounds and molecular targets. Gelomulide N and (E)-5-[(1 S,4aR,8aR)-2-formyl-5,5,8a-trimethyl-1,4,4a,6,7,8-hexahydronaphthalen-1-yl]-3-(acetoxymethyl)pent-2-enoic acid were identified as potential active compounds. Paeoniae Radix Rubra exhibited notable hypolipidemic, hepatoprotective, and gut microbiota-restoring effects, potentially influencing the mevalonate pathway by interacting with proteins such as P53, HMGCR, and SREBP2, which may contribute to reduced cholesterol synthesis. These findings indicate that the Paeoniae Radix Rubra could serve as a potential therapeutic strategy for hyperlipidemia, possibly mediated through modulation of lipid metabolism pathways and gut microbiota remodeling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.